Proteochondroitin sulfate is a major constituent of the cartilage matrix
and all other connective tissue. It plays an important role in bone and
connective tissue metabolism, wound healing, and in cell interactions.
Defective synthesis of these molecules could impact upon diseases and
conditions such as arthritis, atherosclerosis, improper wound healing,
etc. Better knowledge of the biosynthesis and its regulation may assist
in providing rational therapies for these conditions.
Proteochondroitin sulfates consist of a protein backbone to which many
glycosaminoglycan chains of varying chain length and sulfate content are
covalently attached. The chondroitin chains are linked to a wide range
of core protein families. The functions of these proteoglycans are not
clearly defined, but may be as varied as their structures. It is
unclear how the protein core and the highly anionic sulfated
glycosaminoglycan structures direct these functions, but it is likely
that the core protein would be involved in channeling the transport and
presentation of the attached glycosaminoglycans to specific
intracellular granule, cell surface, or matrix localities. Whether or
not this is a main function of the protein core, it does seem apparent
that the fine structure of the highly anionic glycosaminoglycans may be
of paramount importance in function at each location where the
proteoglycans are presented. It is not clear at present as to what key
features control the biosynthesis of the fine structure of the
chondroitin sulfate chains.
Our goal is to examine the assembly of the polysaccharide portion of
proteochondroitin sulfate. Although the main outlines of the
biosynthetic pathway are now clear, several areas remain to be explored.
These include the organization, sub-cellular localization, movement and
interaction of nascent proteoglycan and enzyme for synthesis of the
polysaccharide portion of proteochondroitin sulfate. We will use a
chick embryo epiphyseal cartilage system that synthesizes at least two
populations of proteochondroitins that are predominantly 6-sulfated and
a mast cell system that synthesizes an intracellular proteochondroitin
4-sulfate. In order to examine the organization of the enzymes involved
in synthesis, we will sub-fractionate the Golgi followed by functional
characterization of the fractions. These fractions will be assayed for
xylosyl transferase, two galactosyl transferases, N-acetylgalactosaminyl
transferase(s), glucuronosyl transferase(s), 4-sulfotransferase, 6-
sulfotransferase and specific marker enzymes. In addition, N-
acetylgalactosaminyl transferase, glucuronosyl transferase and
sulfotransferases will be purified to homogeneity, employing
conventional protein purification techniques as well as affinity
chromatographic techniques. The fundamental characteristics and
specificities of these enzymes will be determined. The interactions of
the enzymes with each other to form multi-enzyme complexes will be
examined. This will provide the basis for the long-term goal which is
to reconstitute proteochondroitin sulfate synthesis with the purified
enzymes, raise antibodies to the purified enzymes and to clone them.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
DUNS Number
030811269
UEI
QN6MS4VN7BD1
Project Start Date
01-May-1993
Project End Date
30-April-1996
Budget Start Date
01-May-1994
Budget End Date
30-April-1995
Project Funding Information for 1994
Total Funding
$118,019
Direct Costs
$88,736
Indirect Costs
$29,283
Year
Funding IC
FY Total Cost by IC
1994
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$118,019
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AR041649-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AR041649-02
Patents
No Patents information available for 5R01AR041649-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AR041649-02
Clinical Studies
No Clinical Studies information available for 5R01AR041649-02
News and More
Related News Releases
No news release information available for 5R01AR041649-02
History
No Historical information available for 5R01AR041649-02
Similar Projects
No Similar Projects information available for 5R01AR041649-02